Check Point Software Technologies Ltd. (NASDAQ:CHKP) shares increased 1.35% in last trading session and ended the day at $81.71. CHKP Gross Margin is 88.40% and its has a return on assets of 13.80%. Check Point Software Technologies Ltd. (NASDAQ:CHKP) quarterly performance is 2.07%.
On 15 December, it was reported Avanan, the one-click cloud security company, has announced a partnership with Check Point Software Technologies (NASDAQ:CHKP), the largest pure-play security vendor globally, to drive change in enterprise-level cloud app protection. Avanan provides leading security solutions for the cloud, and with this partnership, will now offer cloud-based versions of Check Point’s data protection solutions for malware, data loss and encryption to safeguard Office 365, Box, Google Apps, Salesforce and other enterprise SaaS applications.
American Electric Technologies, Inc (NASDAQ:AETI) ended the last trading day at $2.05. Company weekly volatility is calculated as 15.78% and price to cash ratio as 1.84. American Electric Technologies, Inc (NASDAQ:AETI) showed a weekly performance of -13.87%.
TheStreet lowered shares of American Electric Technologies, Inc. (NASDAQ:AETI) from a hold rating to a sell rating in a research report released on Tuesday, Marketbeat.com reports.
On 21 December, Align Technology Inc. (NASDAQ:ALGN) shares increased 0.08% and was closed at $64.21. ALGN EPS growth in last 5 year was 42.80%. Align Technology Inc. (NASDAQ:ALGN) year to date (YTD) performance is 14.85%.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) shares increased 22.33% in last trading session and ended the day at $1.26. AVEO has a return on assets of -66.90%. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) quarterly performance is -5.26%.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) and EUSA Pharma announced an exclusive license agreement in which AVEO has granted EUSA Pharma European rights to tivozanib for the treatment of advanced renal cell carcinoma (“RCC”). The agreement also includes a number of additional territories outside North America, including South America and South Africa, and additional potential indications.
Histogenics Corporation (NASDAQ:HSGX) caters to the Healthcare space. Its weekly performance is -6.43%. On the last day of trading company shares ended up at $2.91. Histogenics Corporation (NASDAQ:HSGX) distance from 50-day simple moving average (SMA50) is -6.57%.
Histogenics Corporation (Histogenics) (NASDAQ:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced that the United States Food and Drug Administration (FDA) has accepted the Company’s amendment filed in November 2015 to the NeoCart Phase 3 clinical trial protocol to expand the eligible patient population.